The growth of the cancer vaccine market is expected to be mainly driven by increasing incidence, rising awareness and access to treatment, and the emergence of novel therapies such as OSE2101 (OSE Immunotherapeutic), Intismeran autogene (Merck/Moderna Therapeutics), CYLEMBIO (IO102-IO103) IO Biotech), Galinpepimut S (SELLAS Life Sciences), BNT113 (BioNTech), RP2 (Replimune), and others..

癌症疫苗市场的增长预计将主要由发病率上升、治疗意识和可及性提高，以及新型疗法的涌现所驱动，例如 OSE2101（OSE Immunotherapeutic）、Intismeran autogene（默克/Moderna Therapeutics）、CYLEMBIO（IO102-IO103，IO Biotech）、Galinpepimut S（SELLAS Life Sciences）、BNT113（BioNTech）、RP2（Replimune）等。

LAS VEGAS

拉斯维加斯

,

，

Sept. 21, 2026

2026年9月21日

/PRNewswire/ -- DelveInsight's Cancer Vaccines Market Size, Target Population, Competitive Landscape & Market Forecast report includes a comprehensive understanding of current treatment practices, addressable patient population, which includes top indications such as Melanoma, Lung Cancer (NSCLC), Bladder Cancer, Prostate Cancer, Breast Cancer, Pancreatic Cancer, Head and Neck Cancer, Cervical Cancer, and Other Solid Tumors.

/美通社/ -- DelveInsight发布的《癌症疫苗市场规模、目标人群、竞争格局与市场预测》报告，全面剖析了当前的治疗实践及可覆盖的患者人群，涵盖黑色素瘤、肺癌（非小细胞肺癌）、膀胱癌、前列腺癌、乳腺癌、胰腺癌、头颈癌、宫颈癌及其他实体瘤等主要适应症。

The selected indications are based on approved therapies and ongoing pipeline activity. The report also provides insights into the emerging cancer vaccines, market share of individual therapies, and current and forecasted market size from 2022 to 2036, segmented into leading markets (the US, EU4, UK, and Japan)..

所选适应症基于已获批的疗法和正在进行的研发管线活动。该报告还提供了对新兴癌症疫苗、各疗法的市场份额以及2022年至2036年当前和预测的市场规模的见解，并按主要市场（美国、欧盟四国、英国和日本）进行细分。

Key Takeaways from the Cancer Vaccines Market Report

癌症疫苗市场报告的关键要点

The cancer therapeutic vaccines market size was found to be

癌症治疗性疫苗市场规模被发现为

~USD 335 million

约3.35亿美元

in the leading markets (the United States, the EU4 (Germany, France, Italy, and Spain), the United Kingdom, and Japan) in 2025.

2025年，在主要市场（美国、欧盟四国（德国、法国、意大利和西班牙）、英国和日本）。

The United States accounted for the largest cancer vaccine market size of the total market size in the 7MM in 2025, i.e.,

2025年，美国在七大主要市场（7MM）中占据了最大的癌症疫苗市场份额，即

87%

87%

compared to other major markets, including the EU4 countries (Germany, France, Italy, and Spain), the United Kingdom, and Japan.

与包括欧盟四大国（德国、法国、意大利和西班牙）、英国和日本在内的其他主要市场相比。

The report provides the total potential number of patients in the indications, such as

该报告提供了各适应症中潜在患者总数，例如

Melanoma, Lung Cancer (NSCLC), Bladder Cancer, Prostate Cancer, Breast Cancer, Pancreatic Cancer, Head and Neck Cancer, Cervical Cancer, and Other Solid Tumors

黑色素瘤、肺癌（非小细胞肺癌）、膀胱癌、前列腺癌、乳腺癌、胰腺癌、头颈癌、宫颈癌及其他实体瘤

.

。

In the 7MM, total cases across selected indications for cancer therapeutic vaccines were highest for prostate cancer, at approximately

在7MM中，选定癌症治疗性疫苗适应症的总病例数以前列腺癌为最高，约为

2.8 million

280万

cases in 2025, and are projected to increase by 2036.

2025年的病例数，并预计到2036年将增加。

Leading companies developing cancer vaccines include

开发癌症疫苗的领先企业包括

OSE Immunotherapeutic, Moderna Therapeutics, Merck, CG Oncology, Os Therapies, Northwest Biotherapeutics, Advent Bioservices, Greenwich Lifesciences, Tuhura Biosciences, Genelux Corporation, Briacell Therapeutics, Oncotherapy Science, Shionogi, Transcode Therapeutics, CanariaBio, Candel Therapeutics, Sellas Life Sciences, BioNTech, Aston Sciences, IO Biotech, .

OSE免疫治疗公司、莫德纳治疗公司、默克公司、CG肿瘤公司、Os治疗公司、西北生物治疗公司、Advent生物服务公司、格林威治生命科学公司、Tuhura生物科学公司、Genelux公司、Briacell治疗公司、Oncotherapy Science公司、盐野义制药公司、Transcode治疗公司、CanariaBio公司、Candel治疗公司、Sellas生命科学公司、BioNTech公司、Aston Sciences公司、IO Biotech公司。

and others.

等等。

Some of the key cancer vaccines in clinical trials include

临床试验中的一些关键癌症疫苗包括

OSE-2101 (TEDOPI), Intismeran Autogene (MRNA-4157/V940), Cretostimogene Grenadenorepvec, OST-HER2, DCVAX, GLSI-100, IFX-HU2.0 (IFX-2.0), Olvimulogene Nanivacirepvec (OLVI-VEC), SV-BR-1-GM (BRIA-IMT), S-588410, SEVIPROTIMUT L, Oregovomab, Aglatimagene Besadenovec (CAN-2409), Galinpepimut-S (GPS), BNT113, AST-301, AST-201, IO102-IO103, .

OSE-2101（TEDOPI）、Intismeran Autogene（MRNA-4157/V940）、Cretostimogene Grenadenorepvec、OST-HER2、DCVAX、GLSI-100、IFX-HU2.0（IFX-2.0）、Olvimulogene Nanivacirepvec（OLVI-VEC）、SV-BR-1-GM（BRIA-IMT）、S-588410、SEVIPROTIMUT L、Oregovomab、Aglatimagene Besadenovec（CAN-2409）、Galinpepimut-S（GPS）、BNT113、AST-301、AST-201、IO102-IO103

and others.

以及其他。

Discover the latest studies on cancer vaccines 2026 @

探索2026年癌症疫苗的最新研究 @

https://www.delveinsight.com/report-store/cancer-vaccines-market

https://www.delveinsight.com/report-store/cancer-vaccines-market

Key Factors Driving the Cancer Vaccines Market

推动癌症疫苗市场发展的关键因素

Rising Global Cancer Burden:

全球癌症负担日益加重：

The increasing incidence of cancer worldwide is creating a greater need for innovative preventive and therapeutic treatment approaches. The growing patient population is expanding the potential demand for cancer vaccines across multiple cancer types.

全球癌症发病率的不断上升，使得对创新预防和治疗手段的需求日益迫切。患者群体的不断扩大，也推动了多种癌症类型对癌症疫苗的潜在需求增长。

Advancements in Cancer Immunotherapy:

癌症免疫疗法的进展：

Rapid progress in immuno-oncology is improving understanding of how the immune system can recognize and attack tumor cells. These advances are supporting the development of therapeutic cancer vaccines designed to generate targeted anti-tumor immune responses.

免疫肿瘤学的快速进展正在提升我们对免疫系统如何识别和攻击肿瘤细胞的理解。这些进步正支持着治疗性癌症疫苗的开发，旨在产生针对性的抗肿瘤免疫反应。

Growth of Personalized Cancer Vaccines:

个性化癌症疫苗的增长：

Advances in genomic sequencing and biomarker identification are enabling the development of personalized vaccines based on individual tumor mutations. Neoantigen-based vaccine approaches are attracting significant interest because of their potential to provide highly targeted treatment.

基因组测序和生物标志物识别的进展，使得基于个体肿瘤突变的个性化疫苗的开发成为可能。基于新抗原的疫苗方法因其提供高度靶向治疗的潜力而受到广泛关注。

Increasing Adoption of mRNA Vaccine Technology:

mRNA疫苗技术的日益普及：

The success of mRNA-based vaccine platforms has accelerated investment and technological development in cancer vaccine research. mRNA platforms offer flexible manufacturing and can potentially encode multiple tumor-specific antigens within a single vaccine.

基于mRNA的疫苗平台的成功加速了癌症疫苗研究领域的投资和技术发展。mRNA平台具有灵活的生产制造优势，并有可能在单一疫苗中编码多种肿瘤特异性抗原。

Expansion of Clinical Trials and Product Pipelines:

临床试验与产品管线的扩展：

Pharmaceutical and biotechnology companies are increasing investments in clinical-stage cancer vaccine candidates targeting melanoma, lung cancer, prostate cancer, pancreatic cancer, and other malignancies. A growing pipeline of candidates such as

制药和生物技术公司正在增加对针对黑色素瘤、肺癌、前列腺癌、胰腺癌及其他恶性肿瘤的临床阶段癌症疫苗候选药物的投资。日益增长的候选药物管线，例如

OSE-2101

OSE-2101

(TEDOPI; OSE Immunotherapeutic),

(TEDOPI；OSE Immunotherapeutic)，

Intismeran Autogene

Intismeran Autogene

(MRNA-4157/V940; Moderna Therapeutics and Merck),

（MRNA-4157/V940；Moderna Therapeutics 和默克公司）

Cretostimogene Grenadenorepvec

克雷托刺激基因 Grenadenorepvec

(CG Oncology),

(CG肿瘤学),

OST-HER2

OST-HER2

(Os Therapies), and others is supporting market expansion and increasing opportunities for commercialization.

（OS疗法）等正在支持市场扩张，并增加商业化机会。

Sadaf Javed, Functional Head of Forecasting & Analytics at DelveInsight, said that prostate cancer is expected to account for ~18% of the cancer therapeutic vaccines market in 2036. Melanoma, breast cancer, NSCLC, and NMIBC are among the fastest-growing segments during 2031–2036.

DelveInsight 预测与分析功能负责人 Sadaf Javed 表示，预计到 2036 年，前列腺癌将占癌症治疗性疫苗市场约 18% 的份额。在 2031 年至 2036 年期间，黑色素瘤、乳腺癌、非小细胞肺癌（NSCLC）和非肌层浸润性膀胱癌（NMIBC）是增长最快的细分市场。

Cancer Vaccines Market Analysis

癌症疫苗市场分析

Cancer vaccines are progressing from an experimental immunotherapy approach toward a more established clinical opportunity, driven by advances in tumor sequencing, neoantigen discovery, mRNA-based platforms, and computational technologies for antigen prediction.

在肿瘤测序、新抗原发现、基于mRNA的平台以及抗原预测计算技术的推动下，癌症疫苗正从一种实验性免疫疗法逐步发展为更为成熟的临床机遇。

Despite these advances, the market continues to face a substantial gap between encouraging immunogenicity and the ability to consistently translate immune responses into meaningful late-stage clinical outcomes.

尽管取得了这些进展，市场仍然面临着一个巨大的差距：一方面免疫原性令人鼓舞，另一方面却难以始终如一地将免疫反应转化为具有临床意义的后期阶段成果。

Melanoma

黑色素瘤

has emerged as a key benchmark for immune-based therapeutic development due to its high immunogenicity, established use of immune checkpoint inhibitors, and the availability of validated oncolytic and immunotherapy approaches.

由于其高免疫原性、免疫检查点抑制剂的成熟应用，以及经过验证的溶瘤病毒和免疫治疗手段的可及性，它已成为基于免疫的治疗开发的关键基准。

At the same time, cancer vaccine development is expanding into challenging solid tumors, including Non-small Cell Lung Cancer (NSCLC), pancreatic cancer, ovarian cancer, prostate cancer, and other tumor types, thereby broadening the potential addressable patient population.

与此同时，癌症疫苗的研发正拓展至具有挑战性的实体瘤领域，包括非小细胞肺癌（NSCLC）、胰腺癌、卵巢癌、前列腺癌以及其他肿瘤类型，从而扩大了潜在的可惠及患者群体。

Although the approved therapeutic landscape remains relatively limited, it is gradually expanding beyond the pioneering cancer vaccine

尽管已获批的治疗格局仍然相对有限，但正逐步超越首创的癌症疫苗，不断拓展。

Sipuleucel-T (PROVENGE)

西普鲁仑-T（PROVENGE）

.

。

Sipuleucel-T continues to represent the established therapeutic cancer vaccine and is approved in the US for the treatment of asymptomatic or minimally symptomatic metastatic castration-resistant prostate cancer (mCRPC). Its demonstrated survival benefit provides clinical validation for the potential of vaccine-based immunotherapy..

Sipuleucel-T 仍然是已确立的治疗性癌症疫苗的代表，在美国获准用于治疗无症状或症状轻微的转移性去势抵抗性前列腺癌（mCRPC）。其证实的生存获益为基于疫苗的免疫疗法的潜力提供了临床验证。

The broader immunotherapy landscape is also receiving regulatory validation through the development of oncolytic viral therapies.

通过溶瘤病毒疗法的发展，更广泛的免疫治疗领域也正获得监管机构的认可。

Talimogene laherparepvec (IMLYGIC) and Teserpaturev/G47Δ (DELYTACT)

塔利莫根拉赫帕雷普韦克（IMLYGIC）和特瑟帕图雷夫/G47Δ（DELYTACT）

established commercial precedents in melanoma and malignant glioma, respectively.

分别在黑色素瘤和恶性胶质瘤领域建立了商业化先例。

In addition,

此外，

Telomelysin (OBP-301/suratadenoturev)

端粒酶溶素（OBP-301/苏拉地诺图雷夫）

received full approval in Japan in 2026 for esophageal cancer.

2026年在日本获得食管癌的全面批准。

More recently,

最近，

Vusolimogene oderparepvec (TUDRIQEV)

Vusolimogene oderparepvec（TUDRIQEV）

received FDA accelerated approval in August 2026 in combination with nivolumab for PD-1-refractory advanced melanoma, further highlighting the potential of localized immune activation and combination-based treatment strategies.

于2026年8月获得美国食品药品监督管理局（FDA）加速批准，与纳武利尤单抗联合用于治疗对PD-1抑制剂耐药的晚期黑色素瘤，进一步凸显了局部免疫激活和基于联合治疗策略的潜力。

The field is increasingly moving toward personalized neoantigen vaccines, supported by advances in tumor sequencing, artificial intelligence-driven antigen prediction, mRNA technologies, and computational platforms.

在肿瘤测序、人工智能驱动的抗原预测、mRNA技术以及计算平台进步的推动下，该领域正日益向个性化新抗原疫苗方向发展。

These technologies enable the development of vaccine candidates tailored to the unique mutational characteristics and antigenic profiles of individual tumors, supporting a more personalized approach to cancer immunotherapy.

这些技术使得能够开发出针对个体肿瘤独特突变特征和抗原谱的候选疫苗，从而支持更加个性化的癌症免疫治疗方法。

Combination therapy has increasingly become a central development strategy, with cancer vaccines frequently being evaluated alongside PD-1/PD-L1 inhibitors and other immune-modulating agents.

联合疗法日益成为核心开发策略，癌症疫苗常与PD-1/PD-L1抑制剂及其他免疫调节剂一同接受评估。

These combinations are intended to strengthen vaccine-induced T-cell responses while addressing the immunosuppressive tumor microenvironment. As a result, cancer vaccines are increasingly being positioned as immune-priming platforms or therapeutic backbones rather than as standalone treatments.

这些联合方案旨在增强疫苗诱导的T细胞反应，同时应对免疫抑制性的肿瘤微环境。因此，癌症疫苗正日益被定位为免疫启动平台或治疗基石，而非作为单一疗法使用。

Earlier-stage disease and minimal residual disease settings represent another significant opportunity for cancer therapeutic vaccines. Patients with lower tumor burden may provide a more favorable setting for vaccine-induced immune control compared with those with heavily advanced or pretreated disease. .

早期疾病和微小残留病灶状态为癌症治疗性疫苗提供了另一个重要机遇。与肿瘤负荷较重或经多线预处理的晚期患者相比，肿瘤负荷较低的患者可能为疫苗诱导的免疫控制提供更有利的环境。

Accordingly, adjuvant, perioperative, and Measurable Residual Disease (MRD)-directed strategies may offer greater opportunities to demonstrate recurrence-free and overall survival benefits.

因此，辅助治疗、围手术期治疗以及针对可测量残留病灶（MRD）的策略可能在展示无复发生存和总生存获益方面提供更大的机会。

The cancer therapeutic vaccines pipeline is highly diversified, encompassing a broad range of late-stage and innovative candidates being developed by leading companies and research organizations.

癌症治疗性疫苗的研发管线高度多元化，涵盖了由领先企业和研究机构开发的众多后期阶段及创新候选产品。

Key candidates include

主要候选人包括

OSE2101, Intismeran autogene, IO102-IO103 (CYLEMBIO), GLSI-100, OST-HER2, DCVax, Aglatimagene besadenovec (CAN-2409), Cretostimogene grenadenorepvec, Olvi-Vec, Seviprotimut L, Oregovomab, S-588410, Galinpepimut S, BNT113, AST-301, AST-201

OSE2101、Intismeran autogene、IO102-IO103（CYLEMBIO）、GLSI-100、OST-HER2、DCVax、Aglatimagene besadenovec（CAN-2409）、Cretostimogene grenadenorepvec、Olvi-Vec、Seviprotimut L、Oregovomab、S-588410、Galinpepimut S、BNT113、AST-301、AST-201

, and other emerging therapeutic vaccine programs.

，以及其他新兴的治疗性疫苗项目。

Learn more about the FDA approved cancer vaccines @

了解更多关于FDA批准的癌症疫苗的信息 @

Approved Cancer Vaccines 2026

2026年获批的癌症疫苗

Cancer Vaccines Competitive Landscape

癌症疫苗竞争格局

Some of the cancer therapeutic vaccines under development include

正在开发的一些癌症治疗性疫苗包括

OSE-2101

OSE-2101

(TEDOPI; OSE Immunotherapeutic),

(TEDOPI；OSE免疫治疗公司)

Intismeran Autogene

Intismeran Autogene

(MRNA-4157/V940; Moderna Therapeutics and Merck),

（MRNA-4157/V940；Moderna Therapeutics 和默克公司）

Cretostimogene Grenadenorepvec

克雷托刺激基因格雷纳多内普维克

(CG Oncology),

(CG Oncology),

OST-HER2

OST-HER2

(Os Therapies),

（操作系统疗法）

DCVAX

DCVAX

(Northwest Biotherapeutics and Advent Bioservices),

（西北生物治疗公司和Advent Bioservices公司）

GLSI-100

GLSI-100

(Greenwich Lifesciences),

（格林威治生命科学公司）

IFX-HU2.0

IFX-HU2.0

(IFX-2.0; Tuhura Biosciences),

(IFX-2.0；Tuhura Biosciences)，

Olvimulogene Nanivacirepvec

奥维穆洛基因 纳米瓦西雷普维克

(OLVI-VEC; Genelux Corporation),

(OLVI-VEC；Genelux公司),

SV-BR-1-GM

SV-BR-1-GM

(BRIA-IMT; Briacell Therapeutics),

(BRIA-IMT；Briacell Therapeutics)，

S-588410

S-588410

(Oncotherapy Science/Shionogi),

（Oncotherapy Science/盐野义）

SEVIPROTIMUT L

左旋塞维普罗替穆特

(Transcode Therapeutics),

(Transcode Therapeutics),

Oregovomab

奥雷戈单抗

(CanariaBio),

（CanariaBio）

Aglatimagene Besadenovec

阿格拉蒂马基因贝萨多诺韦克

(CAN-2409; Candel Therapeutics),

(CAN-2409；Candel Therapeutics)，

Galinpepimut-S

加利肽普特-S

(GPS; Sellas Life Sciences),

(GPS；Sellas Life Sciences)，

BNT113

BNT113

(BioNTech),

（BioNTech）

AST-301

AST-301

(Aston Sciences),

（阿斯顿科学公司）

AST-201

AST-201

(Aston Sciences),

（阿斯顿科学公司）

IO102-IO103

IO102-IO103

(IO Biotech), and others.

(IO Biotech) 等。

OSE Immunotherapeutic's OSE-2101

OSE免疫治疗公司的OSE-2101

is a novel T-cell epitope-based cancer vaccine targeting five tumor-associated antigens. It is designed as an off-the-shelf immunotherapy that activates and differentiates tumor-specific T-cell responses and promotes the expansion of tumor-reactive lymphocytes in HLA-A2-positive cancer patients. According to ClinicalTrials.gov, the Phase III ATALANTE-1 trial evaluating OSE-2101 in patients with advanced or metastatic NSCLC was terminated prematurely due to the COVID-19 pandemic.

是一种基于新型T细胞表位的癌症疫苗，靶向五种肿瘤相关抗原。它被设计为一种现成的免疫疗法，旨在激活和分化肿瘤特异性T细胞反应，并促进HLA-A2阳性癌症患者体内肿瘤反应性淋巴细胞的扩增。根据ClinicalTrials.gov的信息，评估OSE-2101在晚期或转移性非小细胞肺癌（NSCLC）患者中疗效的III期ATALANTE-1试验因新冠疫情而提前终止。

However, encouraging overall survival outcomes observed in patients with secondary resistance to immune checkpoint inhibitors (ICIs) supported continued clinical development. .

然而，在对免疫检查点抑制剂（ICIs）产生继发性耐药的患者中观察到的令人鼓舞的总生存期结果，支持了进一步的临床开发。

OSE-2101 is currently being evaluated in

OSE-2101 目前正在接受评估

ARTEMIA

卤虫

, a new registrational Phase III study comparing the therapy with docetaxel in HLA-A2-positive patients with metastatic NSCLC who have developed secondary resistance to ICIs. Additional Phase II programs include

，一项新的注册性III期研究，在继发免疫检查点抑制剂（ICI）耐药的HLA-A2阳性转移性非小细胞肺癌（NSCLC）患者中，比较该疗法与多西他赛的疗效。其他II期项目包括

CombiTED

CombiTED

, which is evaluating OSE-2101 in combination with nivolumab (OPDIVO) in NSCLC;

，正在评估 OSE-2101 与纳武利尤单抗（OPDIVO）联合用于非小细胞肺癌（NSCLC）的治疗；

TEDOPaM

TEDOPaM

, assessing the therapy with FOLFIRI in pancreatic cancer; and

，评估FOLFIRI方案在胰腺癌中的治疗作用；以及

TEDOVA

TEDOVA

, investigating OSE-2101 alone or in combination with pembrolizumab (KEYTRUDA) in ovarian cancer. The U.S. FDA has granted

，研究 OSE-2101 单药或联合帕博利珠单抗（KEYTRUDA）治疗卵巢癌。美国食品药品监督管理局已授予

Orphan Drug Designation (ODD)

孤儿药资格认定（ODD）

to OSE-2101 for the treatment of NSCLC.

用于 OSE-2101 治疗非小细胞肺癌（NSCLC）。

Moderna Therapeutics and Merck's Intismeran autogene

莫德纳治疗公司与默沙东的Intismeran autogene

is an investigational, personalized mRNA-based Individualized Neoantigen Therapy (INT) that incorporates synthetic mRNA encoding up to 34 patient-specific neoantigens identified from an individual tumor. The therapy is designed to generate a targeted antitumor immune response by stimulating and expanding neoantigen-specific T cells according to the unique mutational profile of each patient's tumor.

是一种在研的、基于mRNA的个性化新抗原疗法（INT），其包含编码多达34种从个体肿瘤中鉴定出的患者特异性新抗原的合成mRNA。该疗法旨在根据每位患者肿瘤的独特突变谱，刺激并扩增新抗原特异性T细胞，从而产生靶向抗肿瘤免疫反应。

Merck and Moderna are advancing the intismeran autogene clinical development program across multiple tumor types and treatment settings, including ongoing Phase III studies in melanoma and NSCLC, as well as additional trials in other solid tumors and earlier-stage disease. In February 2023, the combination of intismeran autogene and pembrolizumab received .

默克公司和莫德纳公司正在推进intismeran autogene在多种肿瘤类型和治疗场景下的临床开发计划，包括正在进行的针对黑色素瘤和非小细胞肺癌（NSCLC）的III期研究，以及在其他实体瘤和更早阶段疾病中的额外试验。2023年2月，intismeran autogene与帕博利珠单抗的联合疗法获得了。

FDA Breakthrough Therapy Designation

FDA突破性疗法认定

for the adjuvant treatment of patients with high-risk melanoma following complete surgical resection. In April 2023, intismeran autogene received

用于高危黑色素瘤患者完全手术切除后的辅助治疗。2023年4月，intismeran autogene获得

PRIME Scheme Designation

PRIME计划认定

from the EMA for the adjuvant treatment of patients with high-risk Stage III/IV melanoma following complete resection.

来自欧洲药品管理局（EMA），用于完全切除后的高风险III/IV期黑色素瘤患者的辅助治疗。

IO Biotech's IO102-IO103

IO Biotech 的 IO102-IO103

is an investigational therapeutic cancer vaccine designed to target both tumor cells and immunosuppressive cells within the tumor microenvironment (TME). The therapy stimulates the activation and expansion of T cells directed against indoleamine 2,3-dioxygenase (IDO) and/or programmed death-ligand 1 (PD-L1)-expressing cells.

是一种研究性治疗性癌症疫苗，旨在靶向肿瘤微环境（TME）中的肿瘤细胞和免疫抑制细胞。该疗法可刺激针对表达吲哚胺2,3-双加氧酶（IDO）和/或程序性死亡配体1（PD-L1）的细胞的T细胞活化与扩增。

Results from the pivotal Phase III .

关键性III期临床试验结果。

IOB-013/KN-D18 trial (NCT05155254)

IOB-013/KN-D18 试验（NCT05155254）

in first-line advanced melanoma were presented at ESMO 2025. Although the combination of IO102-IO103 with pembrolizumab demonstrated a numerical improvement in progression-free survival (PFS), the primary PFS endpoint did not reach statistical significance. Following these findings, the company planned discussions with the FDA regarding the potential design of a new registrational Phase III study.

在2025年欧洲肿瘤内科学会（ESMO）年会上公布了IO102-IO103联合帕博利珠单抗用于一线治疗晚期黑色素瘤的研究结果。尽管该联合疗法在无进展生存期（PFS）方面显示出数值上的改善，但主要终点PFS未达到统计学显著性。基于这些结果，公司计划与美国食品药品监督管理局（FDA）就新的注册性III期临床试验的潜在设计进行讨论。

The Phase II solid-tumor basket study .

II期实体瘤篮子研究

NCT05077709

NCT05077709

has been completed, while

已完成，而

NCT05280314

NCT05280314

is evaluating IO102-IO103 in the neoadjuvant and adjuvant settings for patients with resectable melanoma and squamous cell carcinoma of the head and neck (SCCHN).

正在评估IO102-IO103在可切除黑色素瘤和头颈部鳞状细胞癌（SCCHN）患者新辅助和辅助治疗中的应用。

Candel Therapeutics' CAN-2409

Candel Therapeutics 的 CAN-2409

, also known as

，也称为

aglatimagene besadenovec

阿格拉替马基因贝萨德诺韦克

, is an investigational, off-the-shelf, replication-defective adenoviral therapy designed to deliver the herpes simplex virus thymidine kinase (HSV-tk) gene directly to tumor cells and stimulate a systemic antitumor immune response. Candel is currently evaluating CAN-2409 in NSCLC, borderline-resectable pancreatic ductal adenocarcinoma (PDAC), and localized, non-metastatic prostate cancer.

是一种在研的、现成的、复制缺陷型腺病毒疗法，旨在将单纯疱疹病毒胸苷激酶（HSV-tk）基因直接递送至肿瘤细胞，并激发全身性抗肿瘤免疫反应。Candel 目前正在非小细胞肺癌（NSCLC）、临界可切除胰腺导管腺癌（PDAC）以及局限性、非转移性前列腺癌中评估 CAN-2409。

In May 2026, the company reported new findings from extended follow-up of its randomized, double-blind, placebo-controlled pivotal Phase III trial of aglatimagene besadenovec in patients with intermediate- to high-risk localized prostate cancer. The results showed a consistent clinical benefit across multiple exploratory endpoints and further supported the positive topline findings initially reported in December 2024 following an additional 20 months of follow-up..

2026年5月，公司报告了其针对中高危局限性前列腺癌患者开展的阿格拉蒂马金贝萨多诺韦（aglatimagene besadenovec）随机、双盲、安慰剂对照关键性III期试验的延长随访新发现。结果显示，在多个探索性终点上均观察到一致的临床获益，并进一步支持了此前于2024年12月公布的积极顶线结果，该结果基于额外20个月的随访数据。

The anticipated launch of these emerging therapies are poised to transform the cancer vaccines market landscape in the coming years. As these cutting-edge therapies continue to mature and gain regulatory approval, they are expected to reshape the cancer vaccines market landscape, offering new standards of care and unlocking opportunities for medical innovation and economic growth..

这些新兴疗法的预期上市将在未来几年内改变癌症疫苗市场的格局。随着这些前沿疗法不断成熟并获得监管批准，预计它们将重塑癌症疫苗市场格局，提供新的护理标准，并为医疗创新和经济增长带来机遇。

To know more about leading biopharmaceutical companies developing cancer vaccines, visit @

如需了解更多关于开发癌症疫苗的领先生物制药公司的信息，请访问 @

Cancer Vaccines Market

癌症疫苗市场

Recent Developments in the Cancer Vaccines Market

癌症疫苗市场的最新发展

In

在

August 2026, Merck and Moderna

2026年8月，默克公司与莫德纳公司

announced positive Phase III INTerpath-001 results, with intismeran autogene significantly improving recurrence-free survival (RFS) and distant metastasis-free survival (DMFS) versus KEYTRUDA alone in resected melanoma. It marks the first positive Phase III readout for an individualized neoantigen and mRNA-based cancer therapy..

宣布III期INTerpath-001研究取得阳性结果，与单独使用KEYTRUDA相比，intismeran autogene显著改善了切除后黑色素瘤患者的无复发生存期（RFS）和无远处转移生存期（DMFS）。这标志着个体化新抗原及mRNA癌症疗法首次获得阳性III期临床数据。

In

在

August 2026,

2026年8月，

the US FDA granted accelerated approval to vusolimogene oderparepvec (TUDRIQEV) in combination with nivolumab for adults with unresectable advanced cutaneous melanoma.

美国食品药品监督管理局（FDA）批准vusolimogene oderparepvec（TUDRIQEV）与纳武利尤单抗联合用于成人不可切除的晚期皮肤黑色素瘤。

In

在

August 2026,

2026年8月，

Positive Phase III INTerpath-001 results in completely resected Stage IIB-IV melanoma were presented for Intismeran autogene.

Intismeran autogene 在完全切除的 IIB-IV 期黑色素瘤患者中取得的阳性 III 期 INTerpath-001 研究结果已公布。

In

在

July 2026,

2026年7月，

VCN-01 has FDA/EMA Orphan Drug and FDA Rare Pediatric Disease designations for retinoblastoma, with potential Priority Review Voucher eligibility if FDA approval is obtained by September 30, 2029.

VCN-01 已获得美国食品药品监督管理局（FDA）和欧洲药品管理局（EMA）针对视网膜母细胞瘤的孤儿药认定，以及 FDA 的罕见儿科疾病认定；若能在 2029 年 9 月 30 日前获得 FDA 批准，则有资格获得优先审评券。

In

在

May 2026,

2026年5月，

the US FDA granted Fast Track designation for the treatment of unresectable or metastatic cutaneous melanoma to DOC1021.

美国食品药品监督管理局（FDA）授予DOC1021用于治疗不可切除或转移性皮肤黑色素瘤的“快速通道”资格。

In

在

March 2026, Candel Therapeutics

2026年3月，Candel Therapeutics

is in an ongoing dialogue with the FDA in preparation for the anticipated submission of a BLA for aglatimagene besadenovec in prostate cancer in Q4 2026.

正与美国食品药品监督管理局（FDA）进行持续沟通，为预计于2026年第四季度提交阿格拉蒂马基因贝萨德诺韦克（aglatimagene besadenovec）用于治疗前列腺癌的生物制品许可申请（BLA）做准备。

In

在

January 2026,

2026年1月，

the FDA granted Fast Track Designation (FTD) for HPV16-positive head and neck cancer to BNT113.

美国食品药品监督管理局（FDA）授予BNT113针对HPV16阳性头颈癌的快速通道认定（FTD）。

Cancer Vaccines Epidemiology Segmentation

癌症疫苗流行病学细分

The cancer vaccines market report is a comprehensive and specialized analysis, offering in-depth epidemiological insights for the study period 2022–2036 across the leading markets.

癌症疫苗市场报告是一份全面且专业的分析，为2022年至2036年研究期间的主要市场提供深入的流行病学洞察。

Approximately 10–20%

大约 10–20%

of patients with melanoma develop metastatic disease, with the risk increasing substantially among patients with thicker, ulcerated, or regionally advanced tumors.

部分黑色素瘤患者会发展为转移性疾病，且在肿瘤较厚、溃疡或区域晚期患者中，风险显著增加。

The cancer vaccines target patient pool is segmented into:

癌症疫苗的目标患者群体细分为：

Total Eligible Patient Pool for Cancer Vaccines in Selected Indications

选定适应症中癌症疫苗的合格患者总池

Total Cases of Selected Indications for Cancer Vaccines

癌症疫苗选定适应症的总病例数

Total Treated Cases in Selected Indications for Cancer Vaccines

选定适应症中癌症疫苗的总治疗病例数

Cancer Vaccines Report Metrics

癌症疫苗报告指标

Details

详情

Study Period

学习周期

2022–2036

2022–2036

Cancer Vaccines Report Coverage

癌症疫苗报告覆盖范围

7MM [The United States, the EU-4 (Germany, France, Italy, and Spain), the United Kingdom, and Japan]

7MM [美国、欧盟四国（德国、法国、意大利和西班牙）、英国和日本]

Cancer Vaccines Market CAGR

癌症疫苗市场复合年增长率

36 %

36%

Cancer Vaccines Market Size in 2025

2025年癌症疫苗市场规模

USD 335 Million

3.35亿美元

Key Cancer Vaccines Companies

主要癌症疫苗公司

OSE Immunotherapeutic, Moderna Therapeutics, Merck, CG Oncology, Os Therapies, Northwest Biotherapeutics, Advent Bioservices, Greenwich Lifesciences, Tuhura Biosciences, Genelux Corporation, Briacell Therapeutics, Oncotherapy Science, Shionogi, Transcode Therapeutics, CanariaBio, Candel Therapeutics, Sellas Life Sciences, BioNTech, Aston Sciences, IO Biotech, Amgen, Daiichi Sankyo, Dendreon Pharmaceuticals, and others.

OSE免疫治疗公司、Moderna Therapeutics、默克公司、CG Oncology、Os Therapies、Northwest Biotherapeutics、Advent Bioservices、Greenwich Lifesciences、Tuhura Biosciences、Genelux Corporation、Briacell Therapeutics、Oncotherapy Science、盐野义制药、Transcode Therapeutics、CanariaBio、Candel Therapeutics、Sellas Life Sciences、BioNTech、Aston Sciences、IO Biotech、安进、第一三共、Dendreon Pharmaceuticals，以及其他公司。

Key Cancer Vaccines

关键癌症疫苗

OSE-2101 (TEDOPI), Intismeran Autogene (MRNA-4157/V940), Cretostimogene Grenadenorepvec, OST-HER2, DCVAX, GLSI-100, IFX-HU2.0 (IFX-2.0), Olvimulogene Nanivacirepvec (OLVI-VEC), SV-BR-1-GM (BRIA-IMT), S-588410, SEVIPROTIMUT L, Oregovomab, Aglatimagene Besadenovec (CAN-2409), Galinpepimut-S (GPS), BNT113, AST-301, AST-201, IO102-IO103, IMLYGIC, DELYTACT, TUDRIQEV, PROVENGE, and others.

OSE-2101（TEDOPI）、Intismeran Autogene（MRNA-4157/V940）、Cretostimogene Grenadenorepvec、OST-HER2、DCVAX、GLSI-100、IFX-HU2.0（IFX-2.0）、Olvimulogene Nanivacirepvec（OLVI-VEC）、SV-BR-1-GM（BRIA-IMT）、S-588410、SEVIPROTIMUT L、Oregovomab、Aglatimagene Besadenovec（CAN-2409）、Galinpepimut-S（GPS）、BNT113、AST-301、AST-201、IO102-IO103、IMLYGIC、DELYTACT、TUDRIQEV、PROVENGE 等。

Scope of the

范围

Cancer Vaccines

癌症疫苗

Market Report

市场报告

Cancer Vaccines Patient Population Forecast

癌症疫苗患者人群预测

Cancer Vaccines Therapeutics Market Size

癌症疫苗治疗市场规模

Cancer Vaccines Pipeline Analysis

癌症疫苗研发管线分析

Cancer Vaccines Market Size and Trends

癌症疫苗市场规模与趋势

Cancer Vaccines Market Opportunity

癌症疫苗市场机遇

Cancer Vaccines Market Unmet Needs

癌症疫苗市场的未满足需求

KOL's Views on Cancer Vaccines

KOL对癌症疫苗的观点

Cancer Vaccines Market Access and Reimbursement

癌症疫苗的市场准入与报销

Download the report to understand the clinical development of cancer vaccines @

下载报告以了解癌症疫苗的临床开发进展 @

Cancer Vaccines Current Status 2026

2026年癌症疫苗现状

Table of Contents

目录

1

1

Cancer Vaccines Market Key Insights

癌症疫苗市场关键洞察

2

2

Cancer Vaccines Market Report Introduction

癌症疫苗市场报告简介

3

3

Executive Summary of Cancer Therapeutic Vaccines

癌症治疗性疫苗执行摘要

4

4

Key Events

关键事件

5

5

Epidemiology and Market Forecast Methodology

流行病学与市场预测方法论

6

6

Cancer Therapeutic Vaccines Market Overview at a Glance

癌症治疗性疫苗市场概览

6.1

6.1

Clinical Landscape Analysis (by Molecule Type and Phase)

临床格局分析（按分子类型和阶段划分）

6.2

6.2

Market Share (%) Distribution by Indications of Cancer Therapeutic Vaccines in 2025

2025年癌症治疗性疫苗按适应症划分的市场份额（%）分布

6.3

6.3

Market Share (%) Distribution by Indications of Cancer Therapeutic Vaccines in 2036

2036年癌症治疗性疫苗按适应症划分的市场份额（%）分布

7

7

Cancer Therapeutic Vaccines: Background and Overview

癌症治疗性疫苗：背景与概述

7.1

7.1

Introduction

简介

7.2

7.2

History

历史

7.3

7.3

Mechanism

机制

7.4

7.4

Tumor Properties to Consider for Cancer Therapeutic Vaccines

癌症治疗性疫苗需考虑的肿瘤特性

7.5

7.5

Categories

分类

7.6

7.6

Advantages

优点

7.7

7.7

Limitations

局限性

8

8

Epidemiology and Patient Population of Cancer Therapeutic Vaccines in the 7MM

七大主要市场癌症治疗性疫苗的流行病学及患者人群

8.1

8.1

Key Findings

主要发现

8.2

8.2

Assumptions and Rationale

假设与理由

8.3

8.3

Epidemiology Scenario in the 7MM

七大主要市场的流行病学情景

8.3.1

8.3.1

Total Cases of Selected Indications for Cancer Therapeutic Vaccines in the 7MM

七大主要市场中癌症治疗性疫苗选定适应症的总病例数

8.3.2

8.3.2

Indication-wise Eligible Cases for Cancer Therapeutic Vaccines in the 7MM

七大主要市场（7MM）中按适应症划分的癌症治疗性疫苗适用病例

8.3.3

8.3.3

Indication-wise Treated Cases for Cancer Therapeutic Vaccines in the 7MM

七大主要市场（7MM）中按适应症划分的癌症治疗性疫苗接种病例数

9

9

Marketed Therapies

上市疗法

9.1

9.1

Competitive Landscape of Marketed Therapies Related to Cancer Therapeutic Vaccines

癌症治疗性疫苗相关上市疗法的竞争格局

9.2

9.2

Talimogene laherparepvec (IMLYGIC): Amgen

塔利莫金·拉赫帕雷普韦克（IMLYGIC）：安进

9.2.1

9.2.1

Product Description

产品描述

9.2.2

9.2.2

Regulatory Milestones

监管里程碑

9.2.3

9.2.3

Other Developmental Activities

其他发展活动

9.2.4

9.2.4

Summary of Pivotal Trials

关键试验总结

9.2.5

9.2.5

Analyst View

分析师观点

9.3

9.3

Teserpaturev (DELYTACT): Daiichi Sankyo

Teserpaturev（DELYTACT）：第一三共

9.4

9.4

Telomelysin (OBP-301/Suratadenoturev): Oncolys BioPharma

端粒溶解素（OBP-301/Suratadenoturev）：Oncolys BioPharma

9.5

9.5

Vusolimogene oderparepvec (TUDRIQEV): Replimune

Vusolimogene oderparepvec（TUDRIQEV）：Replimune

9.6

9.6

Sipuleucel-T (PROVENGE): Dendreon Pharmaceuticals

西普鲁仑-T（PROVENGE）：Dendreon 制药公司

10

10

Emerging Therapies

新兴疗法

10.1

10.1

Competitive Landscape of Emerging Therapies Related to Cancer Therapeutic Vaccines

癌症治疗性疫苗相关新兴疗法的竞争格局

10.2

10.2

OSE-2101 (TEDOPI): OSE Immunotherapeutic

OSE-2101（TEDOPI）：OSE免疫疗法公司

10.2.1

10.2.1

Product Description

产品描述

10.2.2

10.2.2

Regulatory Milestones

监管里程碑

10.2.3

10.2.3

Other Developmental Activities

其他发展活动

10.2.4

10.2.4

Clinical Development

临床开发

10.2.4.1

10.2.4.1

Clinical Trials Information

临床试验信息

10.2.5

10.2.5

Safety and Efficacy

安全性与有效性

10.2.6

10.2.6

Analyst View

分析师观点

10.3

10.3

Intismeran Autogene (MRNA-4157/V940): Moderna Therapeutics And Merck

Intismeran Autogene（MRNA-4157/V940）：莫德纳治疗公司与默克公司

10.4

10.4

Cretostimogene Grenadenorepvec: CG Oncology

克雷托刺激基因格雷纳多诺普维克：CG肿瘤学

10.5

10.5

OST-HER2: Os Therapies

OST-HER2：奥希替尼疗法

10.6

10.6

DCVAX: Northwest Biotherapeutics and Advent Bioservices

DCVAX：西北生物治疗公司与Advent Bioservices

10.7

10.7

GLSI-100: Greenwich Lifesciences

GLSI-100：格林威治生命科学公司

10.8

10.8

IFX-HU2.0 (IFX-2.0): Tuhura Biosciences

IFX-HU2.0（IFX-2.0）：Tuhura Biosciences

10.9

10.9

Olvimulogene Nanivacirepvec (OLVI-VEC): Genelux Corporation

Olvimulogene Nanivacirepvec（OLVI-VEC）：Genelux公司

10.10

10.10

SV-BR-1-GM (BRIA-IMT): Briacell Therapeutics

SV-BR-1-GM（BRIA-IMT）：Briacell Therapeutics

10.11

10.11

S-588410: Oncotherapy Science/Shionogi

S-588410：Oncotherapy Science/盐野义

10.12

10.12

SEVIPROTIMUT L: Transcode Therapeutics

SEVIPROTIMUT L：Transcode Therapeutics

10.13

10.13

Oregovomab: CanariaBio

奥瑞戈莫单抗：CanariaBio

10.14

10.14

Aglatimagene Besadenovec (CAN-2409): Candel Therapeutics

阿格拉替马根贝萨德诺韦（CAN-2409）：Candel Therapeutics

10.15

10.15

Galinpepimut-S (GPS): Sellas Life Sciences

Galinpepimut-S（GPS）：Sellas Life Sciences

10.16

10.16

BNT113: BioNtech

BNT113：BioNTech

10.17

10.17

AST-301: Aston Sciences

AST-301：阿斯顿科学公司

10.18

10.18

AST-201: Aston Sciences

AST-201：阿斯顿科学公司

List to be continued…..

列表待续……

11

十一

Cancer Therapeutic Vaccines: Seven Major Market Analysis

癌症治疗性疫苗：七大市场分析

11.1

11.1

Key Findings

主要发现

11.2

11.2

Cancer Vaccines Market Outlook

癌症疫苗市场前景

11.3

11.3

Conjoint Analysis

联合分析

11.4

11.4

Key Cancer Vaccines Market Forecast Assumptions

关键癌症疫苗市场预测假设

11.5

11.5

Total Market Size of Cancer Therapeutic Vaccines by Indications in the 7MM

七大主要市场（7MM）按适应症划分的癌症治疗性疫苗总市场规模

11.6

11.6

Market Size of Cancer Therapeutic Vaccines by Therapies in the 7MM

七大主要市场（7MM）中按疗法划分的癌症治疗性疫苗市场规模

11.7

11.7

The United States Cancer Vaccines Market

美国癌症疫苗市场

11.7.1

11.7.1

Total Market Size of Cancer Therapeutic Vaccines by Indications in the United States

美国按适应症划分的癌症治疗性疫苗总市场规模

11.7.2

11.7.2

Market Size of Cancer Therapeutic Vaccines by Therapies in the United States

美国按疗法划分的癌症治疗性疫苗市场规模

11.8

11.8

EU4 and the UK Cancer Vaccines Market

欧盟四国与英国癌症疫苗市场

11.9

11.9

Japan Cancer Vaccines Market

日本癌症疫苗市场

12

12

Unmet Needs

未满足的需求

13

13

SWOT Analysis

SWOT分析

14

十四

KOL Views

KOL观点

15

十五

Market Access and Reimbursement

市场准入与报销

15.1

15.1

The United States

美国

15.2

15.2

EU4 and the UK

欧盟四国与英国

15.4

15.4

Japan

日本

15.5

15.5

Summary and Comparison of Market Access and Pricing Policy Developments in 2025

2025年市场准入与定价政策发展综述及比较

15.6

15.6

Market Access and Reimbursement of Cancer Therapeutic Vaccines

癌症治疗性疫苗的市场准入与报销

16

十六

Bibliography

参考文献

17

17

Cancer Vaccines Market Report Methodology

癌症疫苗市场报告方法论

Related Reports

相关报告

Cancer Vaccines Competitive Landscape

癌症疫苗竞争格局

Cancer Vaccines Competitive Landscape – 2026

癌症疫苗竞争格局 – 2026

report provides comprehensive insights about the pipeline landscape, pipeline drug profiles, including clinical and non-clinical stage products, and the key cancer vaccine companies, including

报告提供了关于管线格局、管线药物概况（包括临床和非临床阶段产品）以及关键癌症疫苗公司的全面洞察，包括

Imvax, Transgene, BrightPath Biotherapeutics, Vaccitech, Amal Therapeutics, Enterome, Moderna, Inc., Ultimovacs ASA, OSE Immunotherapeutic, IO Biotech, PDS Biotech, LIKANGLIFE SCIENCES, ISA Pharmaceuticals, Voltron Therapeutics, Inc., RNAImmune

Imvax、Transgene、BrightPath Biotherapeutics、Vaccitech、Amal Therapeutics、Enterome、Moderna, Inc.、Ultimovacs ASA、OSE Immunotherapeutic、IO Biotech、PDS Biotech、力康生命科学（LIKANG LIFE SCIENCES）、ISA Pharmaceuticals、Voltron Therapeutics, Inc.、RNAImmune

, and others.

，以及其他。

Prostate Cancer Market

前列腺癌市场

Prostate Cancer Market Insights, Epidemiology, and Market Forecast – 2036

前列腺癌市场洞察、流行病学及市场预测——2036年

report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key prostate cancer companies, including

报告深入解读了该疾病、历史及预测流行病学，以及市场趋势、市场驱动因素、市场壁垒和前列腺癌领域的主要企业，包括

Sanofi, AstraZeneca, Astellas Pharma, Bayer, Novartis, Curium, Merck, Orion, Janssen Pharmaceutical, Pfizer, Exelixis, Ipsen Pharma, Takeda, AB Science, Lantheus, Eli Lilly, POINT Biopharma, Telix Pharmaceuticals, Tavanta Therapeutics, Jiangsu Hengrui Pharmaceuticals, Kangpu Biopharmaceuticals, Fusion Pharma, Merus, Bristol-Myers Squibb, Syntrix Pharmaceuticals, Promontory Therapeutics, Xencor, Taiho Pharmaceutical, Madison Vaccines, MacroGenics, Zenith Epigenetics, Modra Pharmaceuticals, Arvinas, Laekna Therapeutics, Blue Earth Therapeutics, Oncternal Therapeutics, Essa Pharma, Clarity Pharmaceuticals, BioNTech, DualityBio, Daiichi Sankyo, Fortis Therapeutics, ORIC Pharmaceuticals, Amgen,.

赛诺菲、阿斯利康、安斯泰来制药、拜耳、诺华、Curium、默克、奥立安制药、杨森制药、辉瑞、Exelixis、益普生制药、武田制药、AB Science、Lantheus、礼来、POINT Biopharma、Telix Pharmaceuticals、Tavanta Therapeutics、江苏恒瑞医药、康朴生物医药、Fusion Pharma、Merus、百时美施贵宝、Syntrix Pharmaceuticals、Promontory Therapeutics、Xencor、大正制药、Madison Vaccines、MacroGenics、Zenith Epigenetics、Modra Pharmaceuticals、Arvinas、来凯医药、Blue Earth Therapeutics、Oncternal Therapeutics、Essa Pharma、Clarity Pharmaceuticals、BioNTech、DualityBio、第一三共、Fortis Therapeutics、ORIC Pharmaceuticals、安进

and others.

以及其他。

Non-Small Cell Lung Cancer

非小细胞肺癌

Market

市场

Non-Small Cell Lung Cancer

非小细胞肺癌

Market Insights, Epidemiology, and Market Forecast

市场洞察、流行病学及市场预测

–

–

2036

2036

report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key NSCLC companies including

该报告深入剖析了疾病概况、历史及预测流行病学数据，以及市场趋势、市场驱动因素、市场壁垒和包括以下在内的关键非小细胞肺癌（NSCLC）企业

BeiGene

百济神州

, Merus and Partner Therapeutics, Johnson & Johnson Innovative Medicine, Betta Pharma, Xcovery, CStone Pharmaceuticals, Bristol-Myers Squibb, Haihe Biopharma, Taiho Pharmaceutical, Takeda Pharmaceuticals, EMD Serono (Merck KGaA), Eli Lilly and Company, Merck, Regeneron, Sanofi, Ono Pharmaceutical, Novartis, Genentech, Roche, Amgen, Chugai Laboratories, Moderna Therapeutics, Pfizer, GSK, .

Merus、Partner Therapeutics、强生创新制药、贝达药业、Xcovery、基石药业、百时美施贵宝、海河生物制药、大鹏药品工业株式会社、武田制药、默克雪兰诺（默克集团）、礼来公司、默沙东、再生元、赛诺菲、小野药品工业、诺华、基因泰克、罗氏、安进、中外制药、莫德纳、辉瑞、葛兰素史克

and others.

以及其他。

Non-muscle Invasive Bladder Cancer Market

非肌层浸润性膀胱癌市场

Non-muscle Invasive Bladder Cancer

非肌层浸润性膀胱癌

Market Insights, Epidemiology, and Market Forecast

市场洞察、流行病学及市场预测

–

–

2036

2036

report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key NMIBC companies including

报告深入阐述了该疾病的认知、历史及预测流行病学，以及市场趋势、市场驱动因素、市场壁垒和关键的NMIBC公司，包括

Merck, Ferring Pharmaceuticals, ImmunityBio, CG Oncology, Pfizer, Fidia Farmaceutici, enGene, Urogen, Theralase, Johnson & Johnson, Roche, AstraZeneca, Protara Therapeutics,

默克、辉凌制药、ImmunityBio、CG Oncology、辉瑞、Fidia Farmaceutici、enGene、Urogen、Theralase、强生、罗氏、阿斯利康、Protara Therapeutics，

and others.

以及其他。

About

关于

DelveInsight

DelveInsight

DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance. Get hassle-free access to all the healthcare and pharma market research reports through our subscription-based platform PharmDelve.

DelveInsight 是一家领先的商业咨询和市场研究公司，专注于生命科学领域。通过提供全面的端到端解决方案，助力制药公司提升业绩。通过我们的订阅制平台 PharmDelve，您可以轻松获取所有医疗保健和制药市场研究报告。

.

。

Contact Us

联系我们

Shruti Thakur

什鲁蒂·塔库尔

[email protected]

[email protected]

+14699457679

+14699457679

SOURCE DelveInsight Business Research, LLP

来源：DelveInsight Business Research, LLP

21

二十一

%

%

more press release views with

更多新闻稿浏览量，通过

Request a Demo

申请演示